Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

Merck MRK announced that the FDA has accepted its supplemental biologics license application (sBLA), seeking expanded use of its blockbuster PD-L1 inhibitor, Keytruda, in cervical cancer. With the FDA granting priority review to the sBLA, a final decision is expected on Jan 20, 2024.